Skip page top navigation FDA Logo--links to FDA home
page Logo of and Link to start page of Office of Regulatory Affairs, 
U.S. Food and Drug Administration U.S. Food and Drug Administration Office of Regulatory Affairs HHS Logo and link to Department of Health and Human Services website

FDA Home Page | Federal-State | Import Program | Compliance | Inspection | Science | ORA Search

IA#66-08,     -------2/9/93  Revised


TYPE OF ALERT: Automatic Detention

PRODUCT      : Adrenal cortex extract or products containing
               adrenal extract, and adrenal cortex injection.

PRODUCT CODE : 66V--99

HARMONIZED
CODE         : 3001

PROBLEM      : New Drug Without An Approved New Drug Application
               (NDA) (DNRD)

PAC FOR
COLLECTION   : 56008H

COUNTRY      : All

MANUFACTURER/
SHIPPER      : All

MANUFACTURER/
SHIPPER I.D.#: N/A


IMPORTER'S
I.D. #       : N/A

CHARGE       : For parenteral drugs for human use containing
               adrenal cortex extract or adrenal cortex
               injection, charge:

               "The article is subject to refusal of admission
               pursuant to Section 801(a)(3) in that it appears
               to be a new drug within the meaning of Section
               201(p) without an approved New Drug Application
               (NDA) [Unapproved New Drug, Section 505(a)]."

RECOMMENDING
OFFICE       : Division of Import Operations & Policy, HFC-170

REASON FOR
ALERT        : Parenteral drugs containing adrenal cortex extract
               or adrenal cortex injection have been marketed for
               numerous years.  There is however a lack of
               substantial evidence of safety and effectiveness
               of these drugs.  The AMA Drug Evaluations, 1971
               First Edition, stated that adrenal cortex
               injection (adrenal cortex extract) is considered
               "an obsolete preparation for treatment of adrenal
               cortical insufficiency."  The AMA Drug Evaluation,
               1973 Second Edition, considers that "there is no
               known medical use for this drug".  FDA's medical
               advisors concur that these drug products are not
               generally recognized as safe and effective for
               labeled indications for human use.

               On March 2, 1989, adrenal cortex extract and
               adrenal cortex injection from all sources and all
               countries were included in the attachment to
               Import Alert #66-41, "Unapproved New Drugs
               Promoted in the United States" which instructs
               automatic detention of these products.

INSTRUCTIONS : Automatically detain all parenteral drugs for
               human use containing adrenal cortex extract, or
               adrenal cortex injection.

PRIORITIZATION
GUIDANCE     : N/A

FOI          : No purging is required.

KEYWORDS     : Adrenal Cortex Injection, Adrenal Cortex Extract,
               New Drug

PREPARED BY  : Linda A. Wisniowski, DIOP, 301-443-6553.